|
|
Oncolytic
Viruses: Clinical Applications as Vectors for the Treatment of Malignant Gliomas
Amish
C. Shah¹,
Dale
Benos¹,
G.
Yancey Gillespie²,
James
M. Markert¹’²
¹Department
of Physiology and Biophysics, University of Alabama at Birmingham, Birmingham,
Alabama, USA.
²Department
of Surgery, Division of Neurosurgery, University of Alabama at Birmingham,
Birmingham, Alabama, USA
Gene
therapy using viral vectors for the treatment of primary brain tumors has proven
to be a promising novel treatment modality.
Much effort in the past has been placed in utilizing replication-defective
viruses to this end but they have shown many disadvantages.
Much recent attention has been focused on the potential of replication-competent
viruses to discriminatingly target, replicate within, and destroy tumor cells
via oncolysis, leaving adjacent post-mitotic neurons unharmed.
The engineered tumor-selective herpes simplex-1 virus (HSV-1) mutants G207 and
HSV1716 have completed Phase I investigations in the treatment of recurrent
high-grade glioma.
The results of these clinical trials are reviewed here.
This review also aims to examine the manipulation and development of other
viruses for the treatment of malignant glioma, including Newcastle disease
virus, reovirus, poliovirus, vaccinia virus, and adenoviruses, in particular the
adenovirus mutant ONYX-015.
Keywords:
clinical trials, G207, gene therapy, HSV 1716, malignant glioma, newcastle
disease virus, oncolytic, ONYX-015 adenovirus, poliovirus replicon, reovirus,
vaccinia
Copyright
© 2003 Kluwer
Academic Publishers. All
rights reserved
Source: http://ipsapp009.kluweronline.com/content/getfile/5042/105/5/abstract.htm
|
